Monoclonal antiendotoxin agent HA-1A (Centoxin)

Inglis, T. J. J.; Lacey, R. W.; Kay, E.; Hawkey, Peter M.; Bodenham, Andrew; Calvert, R. T.

doi:10.1016/0140-6736(93)92651-9

Cited by 4 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional efficacy testing was requested during the FDA review of edobacomab, but the product did not meet the endpoint (improvement of short-term survival) in an additional study 7 . Development of nebacumab was terminated due to excess mortality in sepsis patients who were treated but later diagnosed without Gram-negative bacteraemia 8 . Nebacumab was approved in a number of countries outside the US, and then voluntarily withdrawn from these markets.…”

Section: Nascent Technology: 1980smentioning

confidence: 99%

Anti-infective monoclonal antibodies: perils and promise of development

Reichert

Dewitz

2006

Nat Rev Drug Discov

View full text Add to dashboard Cite

So far, most monoclonal antibodies have been developed for treating cancer or immunological diseases. However, the global spread of infections such as West Nile and corona viruses, and the need to address the potential threat of bioterrorism, has boosted public interest in, and government support of, counter-measures for infectious diseases. The attractive features of monoclonal antibodies, such as high specificity and effective recruitment of the immune system, would seem to make them excellent candidates as anti-infective agents. Here, we analyse trends in the development and approval of anti-infective monoclonal antibodies, and discuss factors that influence their success.

show abstract

Section: Nascent Technology: 1980smentioning

confidence: 99%

Anti-infective monoclonal antibodies: perils and promise of development

Reichert

Dewitz

2006

Nat Rev Drug Discov

View full text Add to dashboard Cite

show abstract

Cellular functions during activation and damage by pathogens: Immunogold studies of the interaction of bacterial endotoxins with target cells

Risco

Silva

1995

Microscopy Res & Technique

View full text Add to dashboard Cite

Bacterial endotoxins (lipopolysaccharides or LPS) are active components of Gram-negative bacteria that act on numerous cellular functions through the processes of cell activation and damage. The molecular mechanisms involved in the "endotoxic phenomenon" are not defined yet, although extensive studies have been carried out. Immunogold and electron microscopy (EM) have contributed to identify the primary target cells of endotoxins and the subcellular systems that receive the direct action of these bacterial agents. Here, we review our studies on immunogold detection of endotoxins in cellular and subcellular systems. The analysis of the interaction between endotoxins and cells was focussed on the following aspects: (1) morphological characteristics of the LPS aqueous suspensions used in experimental work; (2) binding of endotoxins to the plasma membrane of type II pneumocytes and alveolar macrophages (two of their cellular targets), and influence of the state of aggregation of the LPS; (3) movement and distribution of endotoxins inside the cell, from the plasma membrane to the nucleoplasm; and (4) interaction of LPS with microtubules and its effects on the integrity of the microtubular network. These approaches provide information at the molecular level as well as data for the establishment of physiological models of endotoxicity.

show abstract

Is there a Place for Monoclonal Antibodies Against Endotoxin in the Therapy of Sepsis?

Eidelman¹,

Sprung²

1994

Update in Intensive Care and Emergency Medicine

View full text Add to dashboard Cite

Monoclonal antiendotoxin agent HA-1A (Centoxin)

Cited by 4 publications

References 2 publications

Anti-infective monoclonal antibodies: perils and promise of development

Anti-infective monoclonal antibodies: perils and promise of development

Cellular functions during activation and damage by pathogens: Immunogold studies of the interaction of bacterial endotoxins with target cells

Is there a Place for Monoclonal Antibodies Against Endotoxin in the Therapy of Sepsis?

Contact Info

Product

Resources

About